Neuraltus Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to developing and commercializing therapeutics that address critical unmet needs in the treatment of neurodegenerative diseases.
http://www.neuraltus.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Monday
LOAD TIME
0.1 seconds
Neuraltus Pharmaceuticals Inc.
Bryan Miller
2483 E●●●●●●ore Rd
Sui●●●212
Pal●●●lto , California, 94303
United States
View this contact
Neuraltus Pharmaceuticals Inc.
Bryan Miller
2483 E●●●●●●ore Rd
Sui●●●212
Pal●●●lto , California, 94303
United States
View this contact
Neuraltus Pharmaceuticals Inc.
Eric Cheung
2483 E●●●●●●ore Rd
Sui●●●212
Pal●●●lto , California, 94303
United States
View this contact
BUY YOUR DOMAIN
15
YEARS
4
MONTHS
4
DAYS
GODADDY.COM, LLC
WHOIS : whois.godaddy.com
REFERRED : http://registrar.godaddy.com
PAGES IN
THIS WEBSITE
14
SSL
EXTERNAL LINKS
11
SITE IP
198.185.159.144
LOAD TIME
0.125 sec
SCORE
6.2
Neuraltus Pharmaceuticals, Inc. | neuraltus.com Reviews
https://neuraltus.com
Neuraltus Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to developing and commercializing therapeutics that address critical unmet needs in the treatment of neurodegenerative diseases.
neuraltus.com
NP001 Phase 2 Data — Neuraltus Pharmaceuticals, Inc.
http://www.neuraltus.com/np001-phase-2-data
NP001 Phase 2 Data. Get In Touch With Us. NP001 Phase 2 Data. Get In Touch With Us. NP001 Phase 2 Data. NP001 Phase 2 Data. Secondary analyses of Neuraltus Pharmaceuticals’ Phase 2 clinical trial of its investigational treatment NP001 ALS, suggest that a biomarker for systemic inflammation. Additionally, ALS patients with greater baseline inflammation also maintained better vital respiratory capacity, or the amount of air exhaled after the deepest possible inhalation, in the study [Figure 2].
Clinical Trials — Neuraltus Pharmaceuticals, Inc.
http://www.neuraltus.com/clinicaltrials
NP001 Phase 2 Data. Get In Touch With Us. NP001 Phase 2 Data. Get In Touch With Us. NP001 Phase 2 Data.
About Us — Neuraltus Pharmaceuticals, Inc.
http://www.neuraltus.com/about-us
NP001 Phase 2 Data. Get In Touch With Us. NP001 Phase 2 Data. Get In Touch With Us. Driven to Improve the Lives of People Living with Neurodegenerative Diseases. Neuraltus began operations in 2004 based on a broad technology portfolio and intellectual property assembled by the company founders. Neuraltus has received $45 million in financing from leading venture groups, including Latterell Venture Partners and VantagePoint Capital Partners, to support its research and drug development efforts.
Pipeline — Neuraltus Pharmaceuticals, Inc.
http://www.neuraltus.com/pipeline
NP001 Phase 2 Data. Get In Touch With Us. NP001 Phase 2 Data. Get In Touch With Us. Our lead product candidate, NP001, is a novel, proprietary investigational therapy that regulates activated macrophages associated with chronic neurologic diseases including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. NP001 transforms these activated, inflammatory macrophages that are linked to neuronal damage, back to their normal, non-inflammatory state. NP001 i...
Press Releases — Neuraltus Pharmaceuticals, Inc.
http://www.neuraltus.com/press-releases
NP001 Phase 2 Data. Get In Touch With Us. NP001 Phase 2 Data. Get In Touch With Us. April 3, 2017. Retrospective Analysis Finds Amyotrophic Lateral Sclerosis Patients with High Serum C-Reactive Protein (CRP) Levels May Respond to Immune Regulators Like NP001. February 8, 2017. Neuraltus Pharmaceuticals Provides Enrollment Update on Confirmatory Phase 2 Study of NP001 in ALS. September 22, 2016. April 4, 2016. September 21, 2015. July 1, 2015. April 20, 2015. December 9, 2013. October 8, 2013. Neuraltus P...
TOTAL PAGES IN THIS WEBSITE
14
Novel Pilot Clinical Trials for ALS Based on Disease Biomarkers
http://alsnewstoday.com/2015/07/06/novel-pilot-clinical-trials-als-based-disease-biomarkers
This is a short description about myself and what this site is about. I hope you enjoy being here! Novel Pilot Clinical Trials For ALS Based on Disease Biomarkers. July 6, 2015. July 6, 2015. Together with the ALS Finding a Cure Foundation. In San Francisco in collaboration with the Northeast ALS Consortium (NEALS). And the Neuraltus Pharmaceuticals, Inc. With this trial, the research team expects to obtain further insight into ALS cases with overactive inflammation. The other Phase II clinical trial.
Portfolio ::
http://vpcp.com/portfolio
Click on any Company for More Information. Companies Achieving an IPO or M&A Event » » » » ».
Meeting Report | ALS Therapy Development Institute
http://blogs.als.net/category/Meeting-Report.aspx
25th Annual Symposium on ALS/MND Research: Day 1. December 8, 2014. ALS Clinical Trials: What’s Wrong? And updates on NP001, sNN0029, Tirasemtiv and PreFALS. The International Symposium on ALS/MND Research. Is the preeminent meeting of the global ALS/MND community. It brings together hundreds of neuroscientists, neurologists, and associated health professionals for three days in a different country each year. Founded and operated by the MND Association. What’s Wrong with ALS Clinical Research? It is esti...
Latterell Venture Partners - Portfolio
http://www.lvpcapital.com/portfolio.html
Calistoga was recently acquired by Gilead Pharmaceuticals for total proceeds of up to $600 Million. The company was a cancer pharmaceutical company developing cancer treatments targeting PI3. Cellective was acquired by Medimmune for proceeds of up to $175 million. Cellective was developing several new pharmaceuticals treating B Cell related cancers and immune diseases. The technology is based on research by Founder Tom Tedder, Chairman of Immunology at Duke University. Neuraltus is a neuropharmaceutical ...
TOTAL LINKS TO THIS WEBSITE
11
Journey of the Neural Tube
Journey of the Neural Tube. Adventures in Organ Development. I just changed this entire journal to Friends Only. There's no reason to be public anymore. I think the only people who read this journal have LJ accounts. This page was loaded Apr 11th 2018, 5:52 am GMT.
Hoşgeldiniz - NeuralTube
Kişinin kendi savunma sisteminden kaynaklanan bir saldırının Parkinson hastalığına sebep olabileceği ihtimali tartışılmakta. Nature Communications’da 16 Nisan 2014 tarihinde yayınlanan çalışmada Parkinson hastalığına. Deney hayvanlarında yaban mersini meyvesinin Parkinson hastalığı riskini azalttığı bulundu. Kanada'nın Newfoundland şehrindeki Memorial Üniversitesi'nde çalışan bir grup araştırmacı d. Parkinson Hastalığının belirtileri nelerdir? Tarihte Parkinson Hastalığı olan ünlüler kimlerdir?
neuraltubedefectcauses.com - neuraltubedefectcauses Resources and Information.
neuraltubedefects.com - This website is for sale! - neuraltubedefects Resources and Information.
UNDER CONSTRUCTION
Is currently UNDER CONSTRUCTION. This Web site is currently under construction. Please be sure to visit this Web site again in the near future! This is your current default homepage; it has been setup with your new account. To update this Under Construction page, please replace your index.html file.
Neuraltus Pharmaceuticals, Inc.
NP001 Phase 2 Data. Get In Touch With Us. NP001 Phase 2 Data. Get In Touch With Us. Neuraltus Pharmaceuticals, Inc. Is a privately-held biopharmaceutical company dedicated to developing and commercializing therapeutics that address critical unmet needs in the treatment of neurodegenerative diseases.
---------> We'll be back in a flash!!! .
neuralui.com - This website is for sale! - neuralui Resources and Information.
The domain neuralui.com. May be for sale by its owner! The domain neuralui.com. May be for sale by its owner! This page provided to the domain owner free. By Sedo's Domain Parking. Disclaimer: Domain owner and Sedo maintain no relationship with third party advertisers. Reference to any specific service or trade mark is not controlled by Sedo or domain owner and does not constitute or imply its association, endorsement or recommendation.
